Syngene International forms a new subsidiary

The company shall be engaged in the business of manufacturing of pharmaceutical, bio-pharmaceutical and biological products of any kind

0
1753
New Delhi: Syngene Manufacturing Solutions Limited (SMSL), a wholly-owned subsidiary company of Syngene International Limited, was incorporated on August 26, 2022.
The company has an authorised capital of 5,00,00,000 equity shares of Rs. 10 each aggregating to Rs. 50,00,00,000 and subscribed capital of 10,00,000 equity shares of Rs. 10 each aggregating to Rs. 1,00,00,000.
SMSL shall be engaged in the business of manufacturing of pharmaceutical, bio-pharmaceutical, and biological products of any kind.
With a combination of dedicated research facilities for Amgen, Baxter, and Bristol-Myers Squibb as well as two million square feet of specialist discovery, development and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including GSK, Zoetis, and Merck KGaA.